Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FCRL2 mRNA expression is inversely associated with clinical progression in chronic lymphocytic leukemia.

European journal of haematology - 1 Dec 2009

Nückel Holger, Collins Crista H, Frey Ulrich H, Sellmann Ludger, Dürig Jan, Siffert Winfried, Dührsen Ulrich

Abstract excerpt

Fc receptor-like 2 (FCRL2) is highly expressed on B-cell chronic lymphocytic leukemia (B-CLL) cells and could possibly influence disease pathogenesis. Therefore, we investigated FCRL2 mRNA expression in a large cohort with 152 CLL patients in order to assess its role in risk prediction in B-CLL....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ADP-ribosyl Cyclase 1
Share to Gene Expression Regulation, Leukemic
Share to Hematologic Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunoglobulin Heavy Chains

Share to Immunoglobulin Variable Region

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to RNA, Neoplasm

Share to ZAP-70 Protein-Tyrosine Kinase

Source

Identifiers

PMID: 19682311
DOI: 10.1111/j.1600-0609.2009.01328.x

Genes

FCRL2
ZAP70

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19682311-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FCRL2 mRNA expression is inversely associated with clinical progression in chronic lymphocytic leukemia.PMID 19682311Read ↗

FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia.Semantic proximity Read ↗

Fc receptor-like 2 (FCRL2) is a novel marker of low-risk CLL and refines prognostication based on IGHV mutation status.Semantic proximity Read ↗

FCRL1 immunoregulation in B cell development and malignancySemantic proximity Read ↗

Fc receptor‐like 1–5 molecules are similarly expressed in progressive and indolent clinical subtypes of B‐cell chronic lymphocytic leukemiaSemantic proximity Read ↗

FCRL6 distinguishes mature cytotoxic lymphocytes and is upregulated in patients with B‐cell chronic lymphocytic leukemiaSemantic proximity Read ↗

EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia.Semantic proximity Read ↗

The Novel Member of the BCL2 Gene Family, BCL2L12, Is Substantially Elevated in Chronic Lymphocytic Leukemia Patients, Supporting Its Value As a Significant BiomarkerSemantic proximity Read ↗

High-throughput proteomics identifies THEMIS2 as independent biomarker of treatment-free survival in untreated CLLSemantic proximity Read ↗

Roles for the FCRL6 Immunoreceptor in Tumor ImmunologySemantic proximity Read ↗

Update on Fc receptor-like (FCRL) family: new immunoregulatory players in health and diseasesSemantic proximity Read ↗

LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia.Semantic proximity Read ↗

Transferrin receptor-1 and 2 expression in chronic lymphocytic leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.